Lilly’s Zyprexa Off-Label Settlement: Record Fine, Routine Compliance Deal

Lilly agreed to pay $1.4 billion in criminal and civil fines and pled guilty to misbranding its antipsychotic drug Zyprexa in a settlement with the U.S. Department of Justice. Despite the record-breaking sum, however, the terms in the accompanying corporate integrity agreement are similar to previous CIAs

More from Archive

More from Pink Sheet